Month: January 2026

The 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Annual Academic Meeting on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were recently held successfully in Chengdu, Sichuan. Centered on urologic and male genitourinary malignancies, the conference emphasized timeliness and diversity, combining a global perspective with Chinese clinical realities to build a high-level platform for academic exchange and innovation in urologic oncology. During the meeting, Oncology Frontier – Urology Frontier invited Academician Xu Zhang from The Third Medical Center, Chinese PLA General Hospital to share his insights on China’s distinctive achievements in minimally invasive surgery, recent advances in systemic therapy, and their clinical value.

From VEGF-targeted agents to immune-based combinations and novel HIF-2α inhibitors, the expanding therapeutic arsenal for renal cell carcinoma (RCC) has significantly prolonged patient survival. At the same time, it has posed a more demanding challenge for clinicians: how to tailor the optimal treatment for each individual patient and truly achieve precision medicine.

In the treatment pathway of prostate cancer, biochemical recurrence (BCR) represents a critical turning point. Especially for high-risk BCR patients with a short PSA doubling time, how to delay disease progression and improve overall survival (OS) has long been a major clinical concern. At the recent 15th Shanghai Urological Oncology Academic Conference, Oncology Frontier – UroStream invited Professor Stephen J. Freedland from Cedars-Sinai Medical Center to provide an in-depth interpretation of the EMBARK study, including its study rationale, clinical benefits, and individualized treatment strategies for high-risk BCR patients.

For many years, adjuvant therapy for renal cell carcinoma (RCC) remained in a state of “therapeutic vacuum.” RCC is intrinsically resistant to radiotherapy and chemotherapy, and early attempts to introduce targeted therapies into the adjuvant setting failed to deliver meaningful benefits. The success of the KEYNOTE-564 trial has been a turning point—ushering RCC adjuvant therapy into the era of immunotherapy and redefining postoperative management for high-risk patients.

In the era of precision medicine for prostate cancer, individualized clinical decision-making has become a central focus of daily practice. At a recent academic conference on urologic oncology, Professor Hailiang Zhang from Huadong Hospital affiliated with Fudan University shared his clinical perspectives on novel hormonal therapy (NHT) in metastatic prostate cancer. He emphasized that, based on solid evidence from randomized clinical trials, NHT combined with androgen deprivation therapy (ADT) has become the standard first-line treatment for both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Nevertheless, optimal treatment selection requires an integrated assessment of tumor burden, genomic characteristics, patient age, and comorbidities, enabling a truly “tailor-made” approach.

At a recent academic conference on urologic oncology, Professor Jun Guo from Peking University Cancer Hospital & Institute delivered an important presentation systematically reviewing the ten-year journey of Chinese researchers in the field of drug therapy for urothelial carcinoma (UC)—from following international trends to taking a leading role. His lecture focused on the landmark achievements of China-originated antibody–drug conjugates (ADCs), represented by disitamab vedotin (RC48), particularly when combined with immunotherapy. Based on Professor Guo’s presentation, this article aims to showcase the international leap achieved by Chinese research in urologic oncology.

In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting convened leading experts in urologic oncology from across China to discuss cutting-edge diagnostic and therapeutic strategies for genitourinary malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer. During the conference, Professor Jingjing Wang, representing the field of medical oncology, delivered an outstanding presentation grounded in the latest evidence-based data, focusing on precision treatment strategies for metastatic castration-resistant prostate cancer (mCRPC), with particular emphasis on combination regimens involving PARP inhibitors. Based on Professor Wang’s presentation, this article systematically reviews the therapeutic challenges of mCRPC, genetic screening strategies, and the clinical benefits of emerging combination approaches, with the aim of providing practical insights for clinicians.